Xuyun Feng

Sales &Business Manager @ Hangzhou Sanjing Biotech Co., Ltd.

About

🌟Hi, I am Xuyun Feng, Business Manager at Hangzhou Sanjing Biotechnology, a China-based CRO specializing in end-to-end nanobody discovery and antibody engineering services for global biopharma and ADC developers.✨️🔹Focused on supporting early-stage antibody drug development, we offer high-quality nanobody hit discovery, target validation, and lead optimization services, backed by our validated platform covering 100+ popular targets (including HER2, BCMA, TFR1, CDH17).🔹I’m passionate about connecting with partners advancing antibody therapeutics, and always open to discussing how our technical expertise can support your R&D goals.🤝🤝#NanobodyDiscovery #Antibody CRO #ADC #BiotechR&D🧬

Country

City

China

Industry

Biotechnology

Skill

Joint Project Development , Antibody Customized Service , Antibody Drug Target Products , Joint Project Development, Customized Service for Protein Expression, Antibody Customized Service, Antibody Drug Target Products

Experience

Sales &Business Manager

Hangzhou Sanjing Biotech Co., Ltd.

2025-12 - Present · 10 mos

浙江省, 中国

Hangzhou Sanjing Biotech Co., Ltd. Founded in 2022, Hangzhou Sanjing Biotech Co., Ltd. focuses on the research, development and services of nanobodies, providing innovative pharmaceutical companies with high-quality nanobody products and early-stage discovery CRO services. The company is equipped with a comprehensive nanobody discovery platform, concentrating on the early discovery of nanobodies to provide source innovation support for clients’ new drug R&D. To date, Sanjing Biotech has validated more than 100 popular drug targets, established partnerships with multiple pharmaceutical R&D enterprises, and successfully delivered numerous nanobody early-stage R&D projects. Sanjing Biotech operates high-standard modern laboratories and advanced instrument platforms, with a strict quality control system in place. Our R&D team is led by PhDs from Peking University and Zhejiang University, with years of deep expertise in nanobodies and recombinant proteins. Supported by strong academic backgrounds and industrial experience, we collaborate with top universities to continuously drive technological breakthroughs. With excellent quality, efficient delivery, and flexible cooperation models, we are committed to empowering new drug R&D and accelerating the translation and application of innovative achievements.